/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

ALPHA TAU MEDICAL LTD-CL A share price today is $6.9229, up -0.99%. The stock opened at $7 against the previous close of $7.04, with an intraday high of $7.175 and low of $6.915.

style

pb-0

ALPHA TAU MEDICAL LTD-CL A

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$6.9229 -0.0099(-0.99%) DRTS at 13 Mar 2026 12:45 PM Biotechnology

Lowest Today 6.915

Highest Today 7.175

Today’s Open 7

Prev. Close 7.04

52 Week High 8.60

52 Week Low 2.30

Day’s Range: Low 6.915 High 7.175

52-Week Range: Low 2.30 High 8.60

ALPHA TAU MEDICAL LTD-CL A Institutional Holdings

ALPHA TAU MEDICAL LTD-CL A Market Status

Strong Buy: 2

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

ALPHA TAU MEDICAL LTD-CL A Fundamentals

Market Cap 600.26 M

PB Ratio 7.7369

PE Ratio 0.0

Enterprise Value 541.55 M

Total Assets 106.58 M

Volume 199329

ALPHA TAU MEDICAL LTD-CL A Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-25188000 -25.2M, FY22:-33762000 -33.8M, FY21:-27271000 -27.3M, FY20:-8882000 -8.9M, FY19:-8464000 -8.5M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-11686000 -11.7M, Q2/2025:-10114000 -10.1M, Q1/2025:-8691000 -8.7M, Q3/2024:-6924000 -6.9M, Q2/2024:-7369000 -7.4M

About ALPHA TAU MEDICAL LTD-CL A & investment objective

Company Information Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending clinical studies for brain and other cancers. The company is headquartered in Jerusalem, Israel.

Organisation Biotechnology

Employees 125

Industry Biotechnology

CEO Mr. Uzi Sofer

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*